The University of Southampton
University of Southampton Institutional Repository

Association between RSK2 and clinical indexes of primary breast cancer: A meta analysis based on mRNA microarray data

Association between RSK2 and clinical indexes of primary breast cancer: A meta analysis based on mRNA microarray data
Association between RSK2 and clinical indexes of primary breast cancer: A meta analysis based on mRNA microarray data

Background: Although ribosomal protein S6 kinases, 90 kDa, polypeptide 3 (RSK2, RPS6KA3) has been reported to play an important role in cancer cell proliferation, invasion, and migration, including breast cancer, its clinical implication in primary breast cancer patients is not well understood, and there were not many studies to explore the relationship between RSK2 and breast cancer on a clinical level. Methods: A systematic series matrix file search uploaded from January 1, 2008 to November 31, 2017 was undertaken using ArrayExpress and Gene Expression Omnibus (GEO) databases. Search filters were breast cancer, RNA assay, and array assay. Files eligible for inclusion met the following criteria: a) sample capacity is over 100, b) tumor sample comes from unselected patient’s primary breast tumor tissue, and c) expression of RSK2 and any clinical parameters of patients were available from the files. We use median as the cutoff value to assess the association between the expression of RSK2 and the clinical indexes of breast cancer patients. Finding: The meta-analysis identified 13 series matrix files from GEO database involving 3,122 samples that come from patients’ primary breast cancer tissue or normal tissue. The expression of RSK2 in tumor tissues is lower than that in normal tissues [odds ratio (OR), 0.54; 95% credible interval (CI), 0.44–0.67; Cochran’s Q test p = 0.14; I 2 = 41.7%]. Patients with a high expression of RSK2 showed more favorable overall survival [hazard ratio (HR), 0.71; 95% CI, 0.49–0.94; Cochran’s Q test p = 0.95; I 2 = 0.0%] and less potential of distant metastasis (OR, 0.59; 95% CI, 0.41–0.87; Cochran’s Q test p = 0.88; I 2 = 0.0%) and lymph node infiltration (OR, 0.81; 95% CI, 0.65–0.998; Cochran’s Q test p = 0.09; I 2 = 42.8%). Besides, the expression of RSK2 in luminal breast cancer is lower than Cochran’s Q test p = 0.06; I 2 = 63.5%). RSK2 overexpression corresponded with higher histological grade (OR, 1.329; 95% CI, 1.03–1.721; Cochran’s Q test p = 0.69; I 2 = 0.0%). RSK2 expression is also associated with estrogen receptor (ER) and age. Conclusion: The meta-analysis provides evidence that RSK2 is a potential biomarker in breast cancer patients. The expression of RSK2 is distinctive in different intrinsic subtypes of breast cancer, indicating that it may play an important role in specific breast cancer. Further study is needed to uncover the mechanism of RSK2 in breast cancer. Systematic Review Registration: (website), identifier (registration number).

biomarkers, breast cancer, microarray, molecular subtype, prognostic value, ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RSK2)
1664-8021
Zheng, Kun
fb7d2c98-e718-4f1d-a70c-2d346a75993a
Yao, Shuo
1a850602-2928-4f41-99e5-9947eef27a82
Yao, Wei
91b4ef5d-e4fb-4838-a918-131e57f9dd53
Li, Qianxia
40782b20-0b45-47ee-b1e5-7584799b3116
Wang, Yali
1a3c3a0a-b38a-42cc-92d3-aa12c09d8e8c
Zhang, Lili
766d5910-74a7-477b-9fa5-cc8fd2ae11ab
Chen, Xiuqiong
ca0e64e1-d9c3-44eb-90a2-06e4ff6e0b43
Xiong, Huihua
6a3eec01-e7d9-413c-a633-394d01fd623d
Yuan, Xianglin
2cceecc4-5364-4bb0-aa14-3e987f2b659a
Wang, Yihua
f5044a95-60a7-42d2-87d6-5f1f789e3a7e
Zou, Yanmei
21d799e4-91cc-478b-a558-26c540e44e92
Xiong, Hua
5a8c6280-60d6-424b-a05d-7c3e8224097d
Zheng, Kun
fb7d2c98-e718-4f1d-a70c-2d346a75993a
Yao, Shuo
1a850602-2928-4f41-99e5-9947eef27a82
Yao, Wei
91b4ef5d-e4fb-4838-a918-131e57f9dd53
Li, Qianxia
40782b20-0b45-47ee-b1e5-7584799b3116
Wang, Yali
1a3c3a0a-b38a-42cc-92d3-aa12c09d8e8c
Zhang, Lili
766d5910-74a7-477b-9fa5-cc8fd2ae11ab
Chen, Xiuqiong
ca0e64e1-d9c3-44eb-90a2-06e4ff6e0b43
Xiong, Huihua
6a3eec01-e7d9-413c-a633-394d01fd623d
Yuan, Xianglin
2cceecc4-5364-4bb0-aa14-3e987f2b659a
Wang, Yihua
f5044a95-60a7-42d2-87d6-5f1f789e3a7e
Zou, Yanmei
21d799e4-91cc-478b-a558-26c540e44e92
Xiong, Hua
5a8c6280-60d6-424b-a05d-7c3e8224097d

Zheng, Kun, Yao, Shuo, Yao, Wei, Li, Qianxia, Wang, Yali, Zhang, Lili, Chen, Xiuqiong, Xiong, Huihua, Yuan, Xianglin, Wang, Yihua, Zou, Yanmei and Xiong, Hua (2021) Association between RSK2 and clinical indexes of primary breast cancer: A meta analysis based on mRNA microarray data. Frontiers in Genetics, 12, [770134]. (doi:10.3389/fgene.2021.770134).

Record type: Review

Abstract

Background: Although ribosomal protein S6 kinases, 90 kDa, polypeptide 3 (RSK2, RPS6KA3) has been reported to play an important role in cancer cell proliferation, invasion, and migration, including breast cancer, its clinical implication in primary breast cancer patients is not well understood, and there were not many studies to explore the relationship between RSK2 and breast cancer on a clinical level. Methods: A systematic series matrix file search uploaded from January 1, 2008 to November 31, 2017 was undertaken using ArrayExpress and Gene Expression Omnibus (GEO) databases. Search filters were breast cancer, RNA assay, and array assay. Files eligible for inclusion met the following criteria: a) sample capacity is over 100, b) tumor sample comes from unselected patient’s primary breast tumor tissue, and c) expression of RSK2 and any clinical parameters of patients were available from the files. We use median as the cutoff value to assess the association between the expression of RSK2 and the clinical indexes of breast cancer patients. Finding: The meta-analysis identified 13 series matrix files from GEO database involving 3,122 samples that come from patients’ primary breast cancer tissue or normal tissue. The expression of RSK2 in tumor tissues is lower than that in normal tissues [odds ratio (OR), 0.54; 95% credible interval (CI), 0.44–0.67; Cochran’s Q test p = 0.14; I 2 = 41.7%]. Patients with a high expression of RSK2 showed more favorable overall survival [hazard ratio (HR), 0.71; 95% CI, 0.49–0.94; Cochran’s Q test p = 0.95; I 2 = 0.0%] and less potential of distant metastasis (OR, 0.59; 95% CI, 0.41–0.87; Cochran’s Q test p = 0.88; I 2 = 0.0%) and lymph node infiltration (OR, 0.81; 95% CI, 0.65–0.998; Cochran’s Q test p = 0.09; I 2 = 42.8%). Besides, the expression of RSK2 in luminal breast cancer is lower than Cochran’s Q test p = 0.06; I 2 = 63.5%). RSK2 overexpression corresponded with higher histological grade (OR, 1.329; 95% CI, 1.03–1.721; Cochran’s Q test p = 0.69; I 2 = 0.0%). RSK2 expression is also associated with estrogen receptor (ER) and age. Conclusion: The meta-analysis provides evidence that RSK2 is a potential biomarker in breast cancer patients. The expression of RSK2 is distinctive in different intrinsic subtypes of breast cancer, indicating that it may play an important role in specific breast cancer. Further study is needed to uncover the mechanism of RSK2 in breast cancer. Systematic Review Registration: (website), identifier (registration number).

This record has no associated files available for download.

More information

Accepted/In Press date: 30 September 2021
Published date: 1 November 2021
Additional Information: Copyright © 2021 Zheng, Yao, Yao, Li, Wang, Zhang, Chen, Xiong, Yuan, Wang, Zou and Xiong.
Keywords: biomarkers, breast cancer, microarray, molecular subtype, prognostic value, ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RSK2)

Identifiers

Local EPrints ID: 451812
URI: http://eprints.soton.ac.uk/id/eprint/451812
ISSN: 1664-8021
PURE UUID: 6cc37c6f-123b-44bd-91da-bbfe17e9c4f0
ORCID for Yihua Wang: ORCID iD orcid.org/0000-0001-5561-0648

Catalogue record

Date deposited: 28 Oct 2021 16:33
Last modified: 17 Mar 2024 03:39

Export record

Altmetrics

Contributors

Author: Kun Zheng
Author: Shuo Yao
Author: Wei Yao
Author: Qianxia Li
Author: Yali Wang
Author: Lili Zhang
Author: Xiuqiong Chen
Author: Huihua Xiong
Author: Xianglin Yuan
Author: Yihua Wang ORCID iD
Author: Yanmei Zou
Author: Hua Xiong

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×